co-investigators, key personnel, or other significant contributors in this proposed study
A Potential Biomarker of Interstitial Cystitis
Metabolomic Assessment of Interstitial Cystitis Serum and Urine Reveals Diagnostic Utility, in review
Variation in symptoms experienced by women with Interstitial Cystitis
BPS Utilizing Veterans Health Administration Data
This CDC-funded study estimates the prevalence of IC to be about 1% (1.4% in women and 0.55% in men) nationally and uses robust and rigorous diagnostic criteria.
In terms of comorbidities, the CDC-funded study reports an estimated 2.72 comorbidities per patient with IC (significantly higher than patients without IC).
Laden BF, Hoedt AD, Scharfenberg A, Saxena R, Senechal JF, Bresee CT, Barbour KE, Kim J, Freedland SJ, Anger JT. Comorbid Conditions in a Nationwide, Heterogenous Population of Veterans with Interstitial Cystitis/Bladder Pain Syndrome. American Urology Association Conference. May 3rd-6th, 2019 in Chicago, IL, USA.
The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population
Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis
Omics approaches to understanding interstitial cystitis/painful bladder syndrome
You Y, Yang W, Anger JT, Freeman MR, Kim J.* (2012) Omics approaches to understanding interstitial cystitis/painful bladder syndrome/bladder pain syndrome. International Neurourology Journal, 16(4):159-68. PMID: 23346481 PMCID: PMC3547176 *corresponding author
Integration analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo
A synthetic form of frizzled 8-associated antiproliferative factor
Kim J*, Keay SK, You S, Loda M, Freeman MR. (2012) A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2, PLoS ONE, 7(12):e50392. PMID: 23236372 PMCID: PMC3516501 *corresponding author
Alterations in the DNA methylation patterns of Calca, Timp3, Mmp2, and Igf2r associated with chronic cystitis in a cyclosphosphamide-induced mouse model
Urinary Metabolite Profiling Combined with Computational Analysis Predicts Interstitial Cystitis-Associated Candidate Biomarkers
Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis
Differential perturbation of the interstitial cystitis-associated genes of bladder and urethra in rat model
Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases
Chen Z, Kim J. (2016) Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases, BMC Urology, 16(1):11, PMID: 27000794
Are We Ready to Use the Omics Strategies for Precision Medicine? Special Issue, Omics Approaches to Understand Bladder Diseases and Beyond
Waste Product or Biologically Active Tissue?
Urinology Think Tank Study Group: Barasch J, Bavendam T, Birder L, Buffington CA, Campeau L, Dmochowski R, Hewitt S, Hill W, Hoshizaki D, Kim J, Klein J, Norton JM, Seed P, Williams J, Yu W, and Star R (2017) Urine: Waste Product or Biologically Active Tissue? Neurourology and Urodynamics (in press)(manuscript is attached)